#1 Clinical Trials Search in Europe

Study on the Effectiveness and Safety of Clascoterone Solution for Treating Male Pattern Hair Loss

3 1 1

What is this study about?

This clinical trial is focused on studying Androgenetic Alopecia, commonly known as male pattern hair loss. The treatment being tested is a topical solution called Clascoterone, also known by its code name CB-03-01. This solution is applied directly to the skin and is designed to help with hair loss in men.

The purpose of the study is to evaluate how effective and safe the Clascoterone solution is in treating male pattern hair loss. The study will last for a total of 12 months. During the first 6 months, participants will be randomly assigned to use either the Clascoterone solution or a vehicle solution, which does not contain the active ingredient. This part of the study is double-blind, meaning neither the participants nor the researchers know who is receiving which treatment. After this period, all participants will use the Clascoterone solution for another 6 months in a single-blind phase, where only the researchers know the treatment details.

Participants will apply the solution twice a day and will be monitored for changes in hair growth and any side effects. The study aims to provide insights into the potential benefits of Clascoterone for men experiencing hair loss.

1 study initiation

Upon joining the study, the participant will be informed about its course and objectives. The study aims to evaluate the efficacy and safety of clascoterone solution in the treatment of androgenetic alopecia in men.

The participant must provide written consent to participate in the study and meet certain criteria, such as being over 18 years of age and having androgenetic alopecia in specific areas of the head.

2 first part

For the first 6 months, the participant applies the clascoterone solution or the control solution twice daily (BID) to the scalp.

The purpose of this part of the study is to assess changes in hair coverage and the participant’s subjective assessment of hair coverage after 6 months.

3 second part

After completing the first part of the study, the participant enters the second, 6-month phase, in which they apply the clascoterone solution or the control solution in a single-blind fashion.

During this phase, the treatment’s efficacy and safety are continued.

4 follow-up visits

The participant is required to attend regular follow-up clinic visits to assess treatment progress and potential side effects.

These visits are crucial for monitoring the effectiveness and safety of the treatment.

5 end of trial

After the 12-month study period, the participant stops using the solution and undergoes a final evaluation of treatment outcomes.

The final study results are analyzed to assess the long-term effectiveness and safety of the clascoterone solution.

Who Can Join the Study?

  • The patient must be male, at least 18 years of age.
  • The patient must provide written consent to participate in the study.
  • The patient must have mild to moderate androgenetic alopecia at the temples and vertex, rated as III vertex to V on the Norwood-Hamilton scale, with a history of ongoing hair loss.
  • The patient must be willing to maintain the same hairstyle, hair length, and hair color throughout the study.
  • The patient must be willing to follow the study instructions at home and return to the clinic for required visits.
  • The patient must agree to continue the same shampooing frequency and use of other general hair care products throughout the study.
  • The patient must agree to maintain the same dietary and supplementation pattern.
  • Patients who are sexually active with a partner and are not surgically sterile (vasectomy performed at least 6 months prior to treatment) must agree to use an acceptable form of birth control, as described in the consent form. For patients, acceptable forms of contraception include condoms and spermicide in combination with other forms of female contraception. For women, acceptable methods (Pearl Index <1%) would include the use of implants, injectables, combined oral contraceptives, certain intrauterine devices, or being postmenopausal (defined as the absence of menstrual periods for more than 12 consecutive months in women aged 50 years or older), being surgically sterile (hysterectomy, bilateral tubal ligation [at least 6 months prior], or bilateral oophorectomy).

Who Cannot Join the Study?

  • Individuals who are not adult males are not permitted to participate in the study.
  • Individuals with other health problems that may affect the study results are not permitted to participate.
  • Individuals taking other medications or therapies that may interfere with the study substance are not permitted to participate.
  • Individuals who cannot attend regular follow-up appointments are not permitted to participate in the study.
  • Individuals who are allergic to the components of the study substance are not permitted to participate.
  • Individuals who do not consent to participate in the study are not permitted to participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Diamond Clinic Sp. z o.o. Cracow Poland
Dermoklinika – Centrum Medyczne s.c. M. Kierstan J. Narbutt A. Lesiak Lodz Poland

Other Sites

Site Name City Country Status
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher Warsaw Poland
Show more
Eurofins bioskin GmbH Hamburg Germany
Pratia S.A. Skorzewo Poland
Charite Research Organisation GmbH Berlin Germany
Centrum Medyczne All-Med Badania Kliniczne Cracow Poland
Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o. Cracow Poland
Carpe Diem Centrum Medycyny Estetycznej Warsaw Poland
Hautmedizin Bad Soden Studienzentrum GmbH Bad Soden Germany
Eflunr Gskr Berlin Germany
Htbzofrwyd uyw Pcjnxikxbn dkx Ukpqosonszotqmcvsoo drd Jlvpklnj Gychgumvmznfmnerhhnfj Msxsr Mainz Germany
Duulanmigr &zaiexg Pjgow Dqw mira Rtyu Hvnlkiav uoi Kdifiqdj Freiburg Im Breisgau Germany
Eeu Lrgiwi Lublin Poland
Pjgnbbl Sbj z oudv Katowice Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Not recruiting
30.10.2023
Poland Poland
Not recruiting
30.10.2023

Trial locations

Investigated drugs:

Clascoterone is a topical solution that is being studied for the treatment of androgenetic alopecia in men. It works by inhibiting the effects of hormones that can contribute to hair loss. A clinical trial is evaluating the effectiveness and safety of this medication over a six-month period.

Investigated diseases:

Androgenetic alopecia – This is the most common form of hair loss in adult men and women, characterized by a gradual thinning of scalp hair. This process is associated with the action of androgen hormones and genetic predisposition. In men, it typically begins with a receding hairline on the forehead and thinning on the crown. In women, it manifests as even thinning of hair across the entire scalp, rarely leading to complete baldness. The disease progresses slowly, and its severity can vary from person to person. Early symptoms may be subtle, but become more noticeable over time.

Trial ID:
2023-504421-39-00
Protocol code:
CB-03-01/38
NCT ID:
NCT05914805
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on the Effectiveness and Safety of Oral Minoxidil for Women with Androgenetic Alopecia

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Portugal Spain